PhotonPharma Inc, a developer of autologous cancer immunotherapies, announced on Thursday the appointment of William Warren, Ph.D. to its board of directors.
PhotonPharma says that Dr. Warren brings more than three decades of experience in biotechnology innovation, vaccine development, and successful entrepreneurship to guide the company's strategic initiatives and growth trajectory.
Most recently, Dr. Warren served in multiple senior leadership roles at Sanofi Vaccines R&D, including head of Innovation, leading a virtual biotech to advance next-generation influenza vaccines, and head of Global Antigen Design, where his group was responsible for antigen designs to advance projects, invigorate an innovative culture, and explore biology and technology interfaces.
Prior to Sanofi, Dr. Warren was CEO and co-founder of VaxDesign Corporation, which he led through its acquisition by Sanofi in 2010. He also co-founded nScrypt Inc, a company specialising in advanced 3D printing and bioprinting systems, and was a managing partner of Sciperio Inc, an innovative high-technology development company.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis